Assignee
NuCana plc
GB·29 granted patents·22 pending applications·114 citations·filing 2004–2025
Top patents by PatentIndex Score
51 records- 0196US11559542B2Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancerNuCana plc·Filed 2021·Granted Jan 24, 2023·3 cites·19 claims
- 0295US11040051B2Formulation comprising a gemcitabine-prodrugNuCana plc·Filed 2020·Granted Jun 22, 2021·4 cites·20 claims
- 0395US10117888B2Formulation comprising a gemcitabine-prodrugNuCana plc·Filed 2015·Granted Nov 6, 2018·23 cites·29 claims
- 0494US10786523B2Formulation comprising a gemcitabine-prodrugNuCana plc·Filed 2018·Granted Sep 29, 2020·8 cites·24 claims
- 0594US10022390B2Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancerNuCana plc·Filed 2017·Granted Jul 17, 2018·13 cites·20 claims
- 0690USRE47589EPhosphoramidate compounds and methods of useNuCana plc·Filed 2004·Granted Sep 3, 2019·34 cites·25 claims
- 0788US11352387B22′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compoundsNuCana plc·Filed 2020·Granted Jun 7, 2022·2 cites·19 claims
- 0888US10993957B2Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancerNuCana plc·Filed 2018·Granted May 4, 2021·4 cites·25 claims
- 0988US10570168B22′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compoundsNuCana plc·Filed 2015·Granted Feb 25, 2020·5 cites·4 claims
- 1086US10774104B2Diastereoselective synthesis of phosphate derivativesNuCana plc·Filed 2016·Granted Sep 15, 2020·4 cites·26 claims
- 1185US12357652B2Formulations of phosphoramidate derivatives of nucleoside drugsNuCana plc·Filed 2023·Granted Jul 15, 2025·0 cites·20 claims
- 1285US11925658B2Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancerNuCana plc·Filed 2023·Granted Mar 12, 2024·0 cites·10 claims
- 1385US10660912B2Combination therapy for cancerNuCana plc·Filed 2015·Granted May 26, 2020·4 cites·15 claims
- 1484US2025171487A1Synthesis of phosphate derivativesNuCana plc·Filed 2024·Application pending·0 cites
- 1582US10906929B2Phosphoramidate nucleoside derivatives as anticancer agentsNuCana plc·Filed 2017·Granted Feb 2, 2021·2 cites·16 claims
- 1681US10669300B2Methods of separating gemcitabine-phosphate diastereoisomersNuCana plc·Filed 2015·Granted Jun 2, 2020·2 cites·20 claims
- 1780US11414452B2Synthesis of phosphate derivativesNuCana plc·Filed 2018·Granted Aug 16, 2022·1 cites·7 claims
- 1880US10662213B2Gemcitabine prodrugsNuCana plc·Filed 2015·Granted May 26, 2020·3 cites·13 claims
- 1980US2025302859A1Formulations of phosphoramidate derivatives of nucleoside drugsNuCana plc·Filed 2025·Application pending·0 cites
- 2079US12054511B2Synthesis of phosphate derivativesNuCana plc·Filed 2022·Granted Aug 6, 2024·0 cites·26 claims
- 2178US2024293439A1Treatment regimensNuCana plc·Filed 2023·Application pending·0 cites
- 2276US2023226092A1Cancer treatments based on gemcitabine prodrugsNuCana plc·Filed 2022·Application pending·0 cites
- 2375US12054510B22′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compoundsNuCana plc·Filed 2022·Granted Aug 6, 2024·0 cites·8 claims
- 2475US11707477B2Formulation comprising a gemcitabine-prodrugNuCana plc·Filed 2021·Granted Jul 25, 2023·0 cites·11 claims
- 2575US11414451B2Floxuridine synthesisNuCana plc·Filed 2018·Granted Aug 16, 2022·1 cites·32 claims
- 2674US11786544B2Formulations of phosphoramidate derivatives of nucleoside drugsNuCana plc·Filed 2021·Granted Oct 17, 2023·0 cites·9 claims
- 2773US2022323475A1Combination therapy for cancerNuCana plc·Filed 2022·Application pending·0 cites
- 2871US2023192750A1Salts of diphosphate phosphoramidate of nucleosides as anticancer compoundsNuCana plc·Filed 2022·Application pending·0 cites
- 2970US11400107B2Cancer treatmentsNuCana plc·Filed 2017·Granted Aug 2, 2022·1 cites·16 claims
- 3070US2025144128A1Cancer treatmentNuCana plc·Filed 2024·Application pending·0 cites
- 3169US2023149436A1Combination therapyNuCana plc·Filed 2022·Application pending·0 cites
- 3265US11897913B2Synthesis of 3′-deoxyadenosine-5′-O-[phenyl(benzyloxy-L-alaninyl)]phosphate (NUC-738)NuCana plc·Filed 2018·Granted Feb 13, 2024·0 cites·8 claims
- 3365US11603382B2Diastereoselective synthesis of phosphate derivativesNuCana plc·Filed 2020·Granted Mar 14, 2023·0 cites·23 claims
- 3465US2023218655A1Cancer treatmentsNuCana plc·Filed 2022·Application pending·0 cites
- 3564US11040997B2Process for preparing nucleoside prodrugsNuCana plc·Filed 2018·Granted Jun 22, 2021·0 cites·8 claims
- 3664US2021100825A1Cancer treatments based on gemcitabine prodrugsNuCana plc·Filed 2020·Application pending·0 cites
- 3764US2020268783A1Combination therapy for cancerNuCana plc·Filed 2020·Application pending·0 cites
- 3863US2025163096A12' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compoundsNuCana plc·Filed 2024·Application pending·0 cites
- 3963US2021130387A1Phosphoramidate nucleoside derivatives as anticancer agentsNuCana plc·Filed 2021·Application pending·0 cites
- 4062US11629164B2Gemcitabine prodrugsNuCana plc·Filed 2020·Granted Apr 18, 2023·0 cites·10 claims
- 4162US2020345755A1Treatment RegimensNuCana plc·Filed 2018·Application pending·0 cites
- 4262US2022033433A1Process for preparing nucleoside prodrugsNuCana plc·Filed 2021·Application pending·0 cites
- 4360US2025296948A1Synthesis of nucleoside derivativesNuCana plc·Filed 2025·Application pending·0 cites
- 4455US2019022117A1Combination therapyNuCana plc·Filed 2016·Application pending·0 cites
- 4555US2018289733A1Cancer treatments based on gemcitabine prodrugsNuCana plc·Filed 2015·Application pending·0 cites
- 4655US2022024963A1Salt of triphosphate phosphoramidates of nucleotides as anticancer compoundsNuCana plc·Filed 2021·Application pending·0 cites
- 4755US2018369266A1Formulations of phosphoramidate derivatives of nucleoside drugsNuCana plc·Filed 2016·Application pending·0 cites
- 4852US11377467B2Crystalline form of gemcitabineNuCana plc·Filed 2016·Granted Jul 5, 2022·0 cites·5 claims
- 4951US11560400B2Salts of diphosphate phosphoramidate of nucleosides as anticancer compoundsNuCana plc·Filed 2018·Granted Jan 24, 2023·0 cites·27 claims
- 5049US2020197430A1Combination TherapyNuCana plc·Filed 2018·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when NuCana plc files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →